Xenetic Biosciences, Inc.
XBIOHealthcareNASDAQBiotechnology · Last scanned Sep 7, 2026
Scan Results
Daily timeframePart of the healthcare sector, Xenetic Biosciences, Inc. (XBIO) is listed under Biotechnology. The $10.9M market capitalization puts XBIO squarely in micro-cap range for its industry. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.
Market Cap
$10.9M
Beta
2.24
P/E (TTM)
—
P/E (Fwd)
-7.08
EPS (TTM)
$-1.15
EPS (Fwd)
$-0.66
ROE
-47.0%
ROA
-26.8%
Cash
$6.5M
Total Debt
$0
Free CF
-$1.2M
52W Change
53.1%
Annual Financials
Cash vs Debt
Where XBIO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, XBIO finished 45.05% above its 150-day moving average ($2.93) and 52.88% above its 200-day moving average ($2.78). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XBIO overbought or oversold?
At the September 3, 2026 close, XBIO's RSI(14) was 96.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Xenetic Biosciences, Inc. reports $6.5M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$1.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -47.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.7M (2022) to $3.0M (2025), reflecting a 74% increase over the period.
A beta of 2.24 means XBIO is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing XBIO.